NovaShunt Appoints Key Executives to its Management Team in Medical Affairs and Commercial Operations

ZUG, Switzerland, December 3 - NovaShunt today announced the appointment of Dr. Pedro Eerdmans as Chief
Medical Officer and Dan Rose as Vice President of Commercial Operations and
member of the Company's Board of Directors.

"I'm very delighted to welcome these two highly seasoned professionals to
our executive management team which signifies NovaShunt's commitment to
building a strong executive leadership team. Together, Dr. Eerdmans and Mr.
Rose bring a wealth of experience and depth of knowledge of clinical research
and commercial operations in the medical device field to NovaShunt", said
Noel L. Johnson, CEO and President. "Our innovative technology platform has
been proven and we are now moving forward with our final clinical studies for
CE marking and preparing for commercialization of our Implantable Automated
Fluid Management System for the treatment of refractory ascites."

As Chief Medical Officer, Pedro Eerdmans will lead NovaShunt's
Clinical Strategy and manage the European clinical team in all markets. Dr.
Eerdmans has extensive experience in Clinical Research and Medical Devices.
Prior to joining NovaShunt, he was Medical Director at Biosensors responsible
for the global clinical program which included more than 12.000 patients post
marketing registries and over 1800 patients regulatory studies. Additionally,
he spent many years with Medtronic holding management positions in Clinical
Research, Ventures and Technology development. Further Pedro Eerdmans has a
PhD in Pharmacology and has more than 5 years hospital experience in
Orthopedics and Urology. Dr. Eerdmans has authored many peer reviewed papers
and holds a patent in the area of wireless pH measurement in the esophagus.
"It is a great opportunity to join NovaShunt in this early stage and build
the clinical evidence for the AFS system. The AFS system will help a patient
population that is in need of a good solution for their refractory ascites.
The AFS system can significantly improve quality of life, decrease
complications and reduce the burden of refractory ascites patients on the
health systems", said Dr. Eerdmans.

As Vice President of Commercial Operations, Dan Rose will have
responsibility for all sales, marketing and business development activities
and will be an active member of NovaShunt's Board of Directors. Mr. Rose
spent the past seven years in a number of leadership positions at Medtronic.
Most recently, he was Marketing Director for the Coronary and Peripheral
Vascular Division in Western Europe. Prior to that, Mr. Rose was Business
Manager of the Vascular Division in the Nordic region. He also co-founded a
medical device company focused on continuous glucose monitoring technology
and spent time working on early stage venture capital opportunities. "I'm
very excited about joining the company. NovaShunt's implantable technology is
robust, with major applications in several growing markets. The company's
first product is unique and has the potential to improve clinical outcomes
and quality of life for many patients suffering from end-stage liver and
heart failure", said Dan Rose.

About the Automated Fluid Shunt (AFS) System

NovaShunt's lead product is a battery powered implantable pump
system designed to remove excess fluid that collects in the abdominal cavity
of patients with advanced liver disease and congestive heart failure. Liver
disease is present in 2% of the Western population and is the only major
cause of death still increasing every year. Congestive Heart Failure is the
fastest growing cardiac disease in the EU and US, also affecting nearly 2% of
the population. At present NovaShunt is collecting clinical data to prepare
for market launch in Europe in 2010.

About NovaShunt

NovaShunt is a privately owned Swiss medical device company
that aims to become the worldwide leader in design, development, manufacture
and marketing of automated implantable pump systems to manage fluid balance
within the body. NovaShunt is focused on areas of unmet clinical need where
its products can significantly improve clinical outcomes, reduce health care
costs and improve patient quality of life.

    Contact:
    Carina Bossi Suess
    Director Marketing&Communications, Investor and Public Relations
    +41-78-609-56-49
    carina.bossi@novashunt.com
    www.novashunt.com

Contact: Carina Bossi Suess, Director Marketing&Communications, Investor and Public Relations, +41-78-609-56-49, carina.bossi at novashunt.com